Bcr-Abl

The Bcr/Abl fusion protein is localized to the cytoplasm and actin cytoskeleton of hematopoietic cells, and has increased and dysregulated tyrosine kinase activity.

Cat. No.	Product name	CAS No.	Purity
T6650	Sabutoclax	1228108-65-3	98%
T6650	Sabutoclax(BI-97C1) is a pan-Bcl-2 inhibitor, including Bcl-xL, Bcl-2, Mcl-1 and Bfl-1 with IC50 of 0.31 μM, 0.32 μM, 0.20 μM and 0.62 μM, respectively.
T12907	SIAIS178	2376047-73-1	98%
T12907	SIAIS178 is a potent and selective degrader of BCR-ABL based on PROTAC technology (IC50 of 24 nM).
T28374	PF-06651481-00	1391063-17-4	98%
T28374	PF-06651481-00 is a Bosutinib analog and a Bcr-Abl inhibitor.
T10583	Bosutinib D8	T10583	98%
T10583	Bosutinib D8 is a deuterium-labeled Bosutinib. Bosutinib (SKI-606) is a dual Src/Abl inhibitor (IC50s: 1.2 nM/1 nM).
T22378	Nilotinib hydrochloride	923288-95-3	98%
T22378	Nilotinib hydrochloride, the hydrochloride salt form of nilotinib, is an orally bioavailable Bcr-Abl tyrosine kinase inhibitor with antineoplastic activity.
T14925	Cenisertib	871357-89-0	98%
T14925	Cenisertib (AS-703569) is a multi-kinase inhibitor and blocks the activity of Aurora-kinase-A/B, AKT, ABL1, STAT5, and FLT3. Cenisertib inhibits tumor growth in ...
T10488	BCR-ABL-IN-1	188260-50-6	98%
T10488	BCR-ABL-IN-1 is a BCR-ABL tyrosine kinase inhibitor (pIC50: 6.46) and may be used in the research of chronic myelogenous leukemia.
T34656	SKLB 1028	1350544-93-2	98%
T34656	SKLB1028 is a new type of oral multikinase inhibitor of EGFR, FLT3, and Abl. It shows excellent activity in FLT3-driven AML models and considerable potency in CM...
T16545	Pivanex	122110-53-6	98%
T16545	Pivanex is a derivative of Butyric acid and is an orally active HDAC inhibitor. Pivanex has antimetastic and antiangiogenic properties. Pivanex down-regulates bc...
T11961	MBM-55S	2083624-07-9	98%
T11961	MBM-55S is an effective inhibitor of Nek2 with an IC50 of 1 nM. MBM-55S indecus cell cycle arrest and apoptosis thereby inhibiting the proliferation of cancer ce...
T22303	Dasatinib hydrochloride	854001-07-3	98%
T22303	Dasatinib hydrochloride is a highly ATP competitive, potent, orally active inhibitor of dual Src/Bcr-Abl(with Ki values of 16 pM and 30 pM for Src and Bcr-Abl, r...
T7186	CZC-8004	916603-07-1
T7186	CZC-8004 is a pan-kinase(ABL kinase) inhibitor and binds a range of tyrosine kinases.
T21785	AG957	140674-76-6
T21785	Tyrphostin AG957, a tyrosine kinase inhibitor with anti-BCR/ABL tyrosine kinase activity restores beta1 integrin-mediated adhesion and inhibitory signaling in ch...
T11641	N-Desmethyl imatinib	404844-02-6
T11641	N-Desmethyl imatinib is a metabolite of Imatinib, which is a multi-target inhibitor of c-Kit, v-Abl, and PDGFR.
T4618	BGG463	890129-26-7	100%
T4618	BGG463 can inhibit c-ABL-T334I, BCR-ABL and BCR-ABL-T315I variants with a 50% inhibitory concentration (IC50) of 0.25 μM, 0.09 μM and 0.590 μM, respectively.
T16750	Rigosertib	592542-59-1	97.33%
T16750	Rigosertib is a selective and non-ATP-competitive inhibitor of PLK1 (IC50: 9 nM). Rigosertib is a multi-kinase inhibitor and a selective anti-cancer agent, which...
T6348	NVP-BHG712	940310-85-0	97.96%
T6348	NVP-BHG712 is a specific EphB4 inhibitor with ED50 of 25 nM that discriminates between VEGFR and EphB4 inhibition; also shows activity against c-Raf, c-Src and c...
T4191	Multi-kinase inhibitor 1	778274-97-8	98%
T4191	Multi-kinase inhibitor I is a Multi-kinase inhibitor.
T2116	AEE788	497839-62-0	98%
T2116	AEE788 has been used in trials studying the treatment of Cancer, Glioblastoma Multiforme, and Brain and Central Nervous System Tumors.
T30855	CGP77675	234772-64-6	98.23%
T30855	CGP77675 is a potent and selective inhibitor of Src family kinase with IC50s of 5-20 and 40 nM for the phosphorylation of peptide substrates and autophosphorylat...